文献速递泌尿男性生殖肿瘤

68Ga-RM2 PET-MRI与单独MRI在前列腺癌生化复发评估中的比较:单中心、单臂、2/3期影像试验

68Ga-RM2 PET-MRI versus MRI alone for evaluation of patients with biochemical recurrence of prostate cancer: a single-centre, single-arm, phase 2/3 imaging trial.
PubMed 文献 · Lancet Oncol · 2024-02-26

这项单中心单臂2/3期试验在斯坦福大学纳入100例前列腺癌生化复发且常规影像无贡献的患者,评估68Ga-RM2 PET-MRI的诊断表现。68Ga-RM2 PET-MRI阳性69例(69%),单独MRI阳性40例(40%),差异有统计学意义(p<0.0001);病灶分析检出143个 vs 96个(p<0.0001)。作者认为68Ga-RM2 PET-MRI诊断表现优于单独MRI,需进一步前瞻性对比研究。

要点

  • 68Ga-RM2 PET-MRI患者水平阳性69%(69例),单独MRI阳性40%(40例),p<0.0001。
  • 病灶水平68Ga-RM2 PET-MRI检出143个病灶,单独MRI检出96个病灶,p<0.0001。
  • 未报告1级或更严重不良事件。

核心结论

  • 68Ga-RM2 PET-MRI在前列腺癌生化复发患者中诊断表现优于单独MRI。
  • 作者认为需要进一步前瞻性对比研究以更好理解GRPR与PSMA表达模式。

研究设计与样本

  • 单中心、单臂、2/3期影像试验,在美国斯坦福大学进行。
  • 纳入成年(≥18岁)前列腺癌生化复发患者,要求卡氏功能状态评分50或以上,前列腺切除术后前列腺特异性抗原浓度升高0.2 ng/mL或以上,或放疗后较最低点升高2 ng/mL或以上,且常规影像无贡献(CT或MRI阴性,骨扫描阴性)。
  • 所有参与者接受68Ga-RM2 PET-MRI;每份PET扫描由三名独立设盲读者使用标准化评估标准判读。
  • 共筛查209名男性,100例纳入分析;中位随访49.3个月(IQR 36.7-59.2)。
  • 试验注册于ClinicalTrials.gov,NCT02624518,已完成。

主要发现

  • 主要终点达到:68Ga-RM2 PET-MRI阳性69例(69%),单独MRI阳性40例(40%),p<0.0001。
  • 病灶分析中68Ga-RM2 PET-MRI检出143个病灶,单独MRI检出96个病灶,p<0.0001。
  • 未报告1级或更严重不良事件。

关键数值与推荐

  • 主要终点定义:至少30%的患者经68Ga-RM2 PET-MRI检测到一个或多个病灶,且68Ga-RM2 PET-MRI检出显著高于MRI。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 作者指出需要进一步前瞻性对比研究以更好理解GRPR与PSMA表达模式。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: National Comprehensive Cancer Network guidelines include prostate-specific membrane antigen (PSMA)-targeted PET for detection of biochemical recurrence of prostate cancer. However, targeting a single tumour characteristic might not be sufficient to reflect the full extent of disease. Gastrin releasing peptide receptors (GRPR) have been shown to be overexpressed in prostate cancer. In this study, we aimed to evaluate the diagnostic performance of the GRPR-targeting radiopharmaceutical 68Ga-RM2 in patients with biochemical recurrence of prostate cancer. METHODS: This single-centre, single-arm, phase 2/3 trial was done at Stanford University (USA). Adult patients (aged ≥18 years) with biochemical recurrence of prostate cancer, a Karnofsky performance status of 50 or higher, increasing prostate-specific antigen concentration 0·2 ng/mL or more after prostatectomy or 2 ng/mL or more above nadir after radiotherapy, and non-contributory conventional imaging (negative CT or MRI, and bone scan) were eligible. All participants underwent 68Ga-RM2 PET-MRI. The primary outcome was the proportion of patients with PET-positive findings on 68Ga-RM2 PET-MRI compared with MRI alone after initial therapy, at a per-patient and per-lesion level. The primary outcome would be considered met if at least 30% of patients had one or more lesions detected by 68Ga-RM2 PET-MRI and the detection by 68Ga-RM2 PET-MRI was significantly greater than for MRI. Each PET scan was interpreted by three independent masked readers using a standardised evaluation criteria. This study is registered with ClinicalTrials.gov, NCT02624518, and is complete. FINDINGS: Between Dec 12, 2015, and July 27, 2021, 209 men were screened for eligibility, of whom 100 were included in analyses. Median follow-up was 49·3 months (IQR 36·7-59·2). The primary endpoint was met; 68Ga-RM2 PET-MRI was positive in 69 (69%) patients and MRI alone was positive in 40 (40%) patients (p<0·0001). In the per-lesion analysis 68Ga-RM2 PET-MRI showed significantly higher detection rates than MRI alone (143 vs 96 lesions; p<0·0001). No grade 1 or worse events were reported. INTERPRETATION: 68Ga-RM2 PET-MRI showed better diagnostic performance than MRI alone in patients with biochemical recurrence of prostate cancer. Further prospective comparative studies with PSMA-targeted PET are needed to gain a better understanding of GRPR and PSMA expression patterns in these patients. FUNDING: The US Department of Defense.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Duan H, Moradi F, Davidzon GA, et al. 68Ga-RM2 PET-MRI versus MRI alone for evaluation of patients with biochemical recurrence of prostate cancer: a single-centre, single-arm, phase 2/3 imaging trial. Lancet Oncol. 2024. PMID: 38423030. doi:10.1016/S1470-2045(24)00069-X

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。